A Phase 4 interventional study of Recombinant Herpes Zoster Vaccine (Shingrix) in Cardiovascular Disease and Dementia, sponsored by Tor Biering-Sørensen. Active, not recruiting at 2 sites in Denmark. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by Tor Biering-Sørensen · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
DAN-ZOSTER is a nationwide randomized study investigating whether vaccination against herpes zoster (shingles) can reduce the risk of cardiovascular disease and dementia in older adults. Herpes zoster is caused by reactivation of the varicella-zoster virus and becomes more common with increasing age. Some observational studies have suggested that vaccination against herpes zoster may also lower the risk of heart attacks, strokes, and dementia, but this has not been confirmed in randomized clinical trials.
In this study, approximately 162,000 adults aged 65 years or older living in Denmark will be randomly assigned to either receive the recombinant herpes zoster vaccine (Shingrix®) or receive no vaccine. Participants in the vaccine group will receive two doses given 2-6 months apart.
Participants will be identified and invited using Danish national registries and digital mail systems. Information about health outcomes will be collected through nationwide health registries during follow-up.
The main outcomes of the study are major cardiovascular events (heart attack, stroke, or cardiovascular death) and new diagnoses of dementia. The goal of the study is to determine whether herpes zoster vaccination can help prevent these conditions in older adults.
Herpes zoster is caused by reactivation of the varicella-zoster virus and becomes increasingly common with age. In addition to causing acute illness and postherpetic neuralgia, observational studies have suggested that herpes zoster infection may be associated with an increased risk of cardiovascular events and dementia. Some observational studies have also reported lower risks of these outcomes among individuals vaccinated against herpes zoster. However, these findings may be affected by confounding, and randomized evidence is currently lacking.
The DAN-ZOSTER trial is a nationwide pragmatic randomized clinical trial designed to evaluate whether vaccination with the recombinant herpes zoster vaccine (Shingrix®) reduces the risk of major adverse cardiovascular events (MACE) and incident dementia in older adults.
In this open-label trial, approximately 162,000 adults aged 65 years or older will be randomized in a 1:1 ratio to receive the recombinant herpes zoster vaccine or no intervention. Participants randomized to the intervention arm will receive two intramuscular doses of Shingrix® administered 2-6 months apart. Participants randomized to the control arm will receive no study vaccination.
Outcomes and follow-up data will be obtained through linkage with Danish nationwide health registries.
The trial has two dual-primary outcomes: (1) major adverse cardiovascular events, defined as a composite of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death, and (2) incident dementia, defined as Alzheimer's disease, vascular dementia, or unspecified dementia. The study uses an event-driven design with predefined minimum follow-up requirements for each primary outcome.
5,376 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.
This study's enrollment of 168,460 is above the median of 100 across 3,086 interventional studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →Tor Biering-Sørensen is the lead sponsor of 22 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The study has the following exclusion criteria which will be assessed through self-reporting:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Recombinant Herpes Zoster Vaccine (Shingrix)
Control arm, no intervention.
Two doses of Shingrix vaccine spaced 2-6 months apart.
Hospitalization for MACE
Defined as a composite of non-fatal myocardial infarction, non-fatal stroke and cardiovascular death
Time frame: From the first of the two initially booked study visits up to approximately 1 year
New dementia
Defined as a composite of Alzheimer's dementia, vascular dementia and unspecified dementia
Time frame: From the first of the two initially booked study visits up to approximately 3 years
Hospitalization for non-fatal acute coronary syndrome, non-fatal stroke, or cardiovascular death
Defined as a composite of acute coronary syndrome, stroke and cardiovascular death Any I-diagnosis as cause of death
Time frame: From the first of the two initially booked study visits up to approximately 1 year
Hospitalization for any cardiovascular disease
Time frame: From the first of the two initially booked study visits up to approximately 1 year
Hospitalization for stroke
Time frame: From the first of the two initially booked study visits up to approximately 1 year
Hospitalization for myocardial infarction
Time frame: From the first of the two initially booked study visits up to approximately 1 year
Cardiovascular death
Time frame: From the first of the two initially booked study visits up to approximately 1 year
Inpatient and/or outpatient diagnosis of Alzheimer's dementia
Time frame: From the first of the two initially booked study visits up to approximately 3 years
Inpatient and/or outpatient diagnosis of vascular dementia
Time frame: From the first of the two initially booked study visits up to approximately 3 years
Inpatient and/or outpatient diagnosis of unspecified dementia
Time frame: From the first of the two initially booked study visits up to approximately 3 years
Hospitalization for unstable angina
Time frame: From the first of the two initially booked study visits up to approximately 3 years
Acute and/or elective coronary revascularization
Time frame: From the first of the two initially booked study visits up to approximately 3 years
Hospitalization for heart failure
Time frame: From the first of the two initially booked study visits up to approximately 3 years
Hospitalization for pulmonary embolism
Time frame: From the first of the two initially booked study visits up to approximately 3 years
Hospitalization for deep venous thrombosis
Time frame: From the first of the two initially booked study visits up to approximately 3 years
Combined endpoint of deep venous thrombosis and hospitalization for pulmonary embolism
Time frame: From the first of the two initially booked study visits up to approximately 3 years
Hospitalization for a combined end point of acute coronary syndrome, stroke, heart failure and cardiovascular death
Time frame: From the first of the two initially booked study visits up to approximately 3 years
New heart failure
Time frame: From the first of the two initially booked study visits up to approximately 3 years
Hospitalization for ischemic stroke
Time frame: From the first of the two initially booked study visits up to approximately 3 years
Hospitalization for hemorrhagic stroke
Time frame: From the first of the two initially booked study visits up to approximately 3 years
Transient ischemic attack
Time frame: From the first of the two initially booked study visits up to approximately 3 years
Hospitalization for atrial fibrillation
Time frame: From the first of the two initially booked study visits up to approximately 3 years
New atrial fibrillation
Time frame: From the first of the two initially booked study visits up to approximately 3 years
Hospitalization for pericarditis
Time frame: From the first of the two initially booked study visits up to approximately 3 years
Hospitalization for myocarditis
Time frame: From the first of the two initially booked study visits up to approximately 3 years
Hospitalization for endocarditis
Time frame: From the first of the two initially booked study visits up to approximately 3 years
Hospitalization for cardiovascular causes
Time frame: From the first of the two initially booked study visits up to approximately 3 years
All-cause hospitalization
Time frame: From the first of the two initially booked study visits up to approximately 3 years
All-cause death
Time frame: From the first of the two initially booked study visits up to approximately 3 years
Inpatient and/or outpatient diagnosis of new dementia or cognitive impairment
Time frame: From the first of the two initially booked study visits up to approximately 3 years
Inpatient and/or outpatient diagnosis of frontotemporal dementia
Time frame: From the first of the two initially booked study visits up to approximately 3 years
Hospitalization with delirium
Time frame: From the first of the two initially booked study visits up to approximately 3 years
Hospitalization for Herpes Zoster
Time frame: From the first of the two initially booked study visits up to approximately 3 years
Hospitalization for influenza
Time frame: From the first of the two initially booked study visits up to approximately 3 years
Laboratory-confirmed influenza infection
Time frame: From the first of the two initially booked study visits up to approximately 3 years
Hospitalization for an infectious disease
Time frame: From the first of the two initially booked study visits up to approximately 3 years
Plan to share: Yes — In this trial, baseline and endpoint data will be collected from Danish administrative health registries, which are subject to Danish legislation and can only be made available to a third party under certain conditions. Please contact the sponsor-investigator in case of any inquiries.
Supporting information: Study protocol, Statistical analysis plan
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Jun 2029, 38 months after the start.
Of 107 non-industry phase 4 interventional studies under Cardiovascular Diseases, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 76. This study's planned 38 months is below that.
Counting every sponsor, half of 113 studies reached it within 46 months; a quarter within 26 and three quarters within 64.
Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Apr 2029 → Jun 2029 and completion Apr 2029 → Jun 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Shingrix
Tor Biering-Sørensen